Legal implications of deprescribing: a case scenario

Barnett, Nina; Kelly, Órla

doi:10.1002/psb.1552

Cited by 6 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to note that continuing a medication that has no current indication and that has a potential to cause medication-related harm is not in the best interests of the patient. Prescribers who continue to prescribe a medication without providing the benefits and options for deprescribing could be exposed to clinical negligence cases, and would not meet the full legal requirements for informed consent as described by Barnett and Kelly [20].…”

Section: Risks and Benefits Of Deprescribingmentioning

confidence: 99%

“…This evidence base decreases as co-morbidities and medications increase and decreases further with age, with older patients rarely included in randomised controlled trials. As single condition guidelines for prescribing rarely contain guidance on stopping a medication, prescribers can be left feeling unsupported and may fear the risk of litigation if something were to happen to the patient [20].…”

Section: Deprescribing and The Lawmentioning

confidence: 99%

See 1 more Smart Citation

Deprescribing: Practical Ways to Support Person-Centred, Evidence-Based Deprescribing

2019

Self Cite

View full text Add to dashboard Cite

Deprescribing is complex and multifactorial with multiple approaches described in the literature. Internationally, there are guidelines and tools available to aid clinicians and patients to identify and safely withdraw inappropriate medications, post a shared decision-making medicines optimisation review. The increase in available treatments and use of single disease model guidelines have led to a healthcare system geared towards prescribing, with deprescribing often seen as a separate activity. Deprescribing should be seen as part of prescribing, and is a key element in ensuring patients remain on the most appropriate medications at the correct doses for them. Due to the complex nature of polypharmacy, every patient experience and relationship with medications is unique. The individual’s history must be incorporated into a patient-centred medication review, in order for medicines to remain optimal through changes in circumstance and health. Knowledge of the law and appropriate recording is important to ensure consent is adequately gained and recorded in line with processes followed when initiating a medication. In recent years, with the increase in interested clinicians globally, a number of prominent networks have grown, creating crucial links for both research and sharing of good practice.

show abstract

Section: Risks and Benefits Of Deprescribingmentioning

confidence: 99%

Section: Deprescribing and The Lawmentioning

confidence: 99%

Deprescribing: Practical Ways to Support Person-Centred, Evidence-Based Deprescribing

2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, educational interventions focusing on geriatric pharmacotherapy can enable clinicians to optimise prescribing. 28 In order to uphold safe practice and reduce the risk of clinical negligence, a prescriber should consider the following: 29 • Prescribing (and the reverse -deprescribing) must be evidence based and/or in line with the decisions of a reasonable body of their peers.…”

Section: Barriers To Deprescribingmentioning

confidence: 99%

Optimising medication in frail older people

Jiwa¹

2018

Prescriber

View full text Add to dashboard Cite

show abstract

“…However, a search of the legal databases (Lexis, Westlaw) and medicines-related databases (Medline, Embase) revealed no cases of pharmacy challenge relating to informed consent despite pharmacists' patient-facing roles. Recent discussion in the pharmacy literature [9][10][11] has highlighted the potential for improvements to medicinesrelated consultation to take account of the requirements for informed consent.…”

Section: Nina Barnett and Claudia Carrmentioning

confidence: 99%